Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$39.27
+0.6%		$34.60
$19.72
▼
$40.30
$3.08B0.87964,988 shs52,644 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$36.16
+0.1%		$33.95
$22.09
▼
$40.58
$3.18B-0.11.10 million shs71,087 shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$7.34
$8.00
$6.08
▼
$12.61
$777.75M1.221,022 shs100 shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$47.50
$45.47
$35.93
▼
$83.12
$3.40B0.88344 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+3.61%+9.75%+1.77%+13.55%+79.13%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+2.01%-0.14%-4.09%+25.64%+44.44%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-8.25%-8.25%-7.38%-8.82%+21.93%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.00%+2.10%+1.17%-2.63%-9.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$39.27
+0.6%		$34.60
$19.72
▼
$40.30
$3.08B0.87964,988 shs52,644 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$36.16
+0.1%		$33.95
$22.09
▼
$40.58
$3.18B-0.11.10 million shs71,087 shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$7.34
$8.00
$6.08
▼
$12.61
$777.75M1.221,022 shs100 shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$47.50
$45.47
$35.93
▼
$83.12
$3.40B0.88344 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+3.61%+9.75%+1.77%+13.55%+79.13%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+2.01%-0.14%-4.09%+25.64%+44.44%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-8.25%-8.25%-7.38%-8.82%+21.93%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.00%+2.10%+1.17%-2.63%-9.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.86
Moderate Buy$54.6239.08% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.81
Moderate Buy$50.2538.97% Upside
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
2.00
HoldN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
2.22
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest OXBDF, ZLDPF, IDYA, and CLDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$58.00 ➝ $60.00
7/29/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $72.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$54.00 ➝ $48.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$44.00 ➝ $40.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$67.00 ➝ $61.00
7/22/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$62.00 ➝ $60.00
7/22/2026
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/20/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$90.00 ➝ $100.00
7/17/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M2,001.50N/AN/A$7.93 per share4.95
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$218.71M14.53N/AN/A$11.67 per share3.10
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$164.59M4.73N/AN/A$0.62 per share11.84
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$1.40B2.44$13.81 per share3.44$31.61 per share1.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/10/2026 (Estimated)
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-$46.74MN/AN/A56.46N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$977.29M$13.483.5234.17N/A68.82%41.80%38.49%8/13/2026 (Estimated)

Latest OXBDF, ZLDPF, IDYA, and CLDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026N/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$0.1431N/AN/AN/A$128.91 millionN/A
8/10/2026Q2 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.06-$1.22-$0.16-$1.22$8.02 million$8.86 million
8/6/2026Q2 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.06N/AN/AN/A$0.74 millionN/A
5/7/2026Q1 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million
5/7/2026Q1 2026
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$1.3652-$0.87+$0.4952-$0.87$2.81 million$5.33 million
5/5/2026Q1 2026
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
8.92
8.92
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
10.74
10.74
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.02
37.17
37.17

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.70%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.49 million74.41 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.86 million83.73 millionOptionable
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
891105.96 millionN/ANot Optionable
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
34071.53 millionN/ANot Optionable

Recent News About These Companies

Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Time to Buy?
August 3 at 2:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zealand-pharma-as-otcmktszldpf-shares-gap-up-time-to-buy-2026-08-03/
Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zealand-pharmas-new-psoriasis-trial-sets-early-stage-for-zp9830?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zealand-pharma-advances-first-in-human-obesity-drug-trial-with-zp6590?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume - Time to Buy?
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zealand-pharma-as-otcmktszldpf-sees-strong-trading-volume-time-to-buy-2026-07-23/
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
July 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-28-2026-1036319087
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of "Hold" by Analysts
July 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zealand-pharma-as-otcmktszldpf-given-consensus-recommendation-of-hold-by-analysts-2026-07-12/
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
July 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-27-2026-1036300031
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
June 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/total-number-of-shares-and-voting-rights-in-zealand-pharma-as-of-june-30-2026-1036288061
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
June 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-major-shareholder-announcement-the-capital-group-companies-inc-1036288056
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
June 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-26-2026-1036283224
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
June 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-25-2026-1036265764
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
June 19, 2026  |  cnbc.comhttps://www.cnbc.com/2026/06/19/zealand-pharma-stock-weight-loss-drugmaker-novo-lilly.html
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
June 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-24-2026-1036249982
Drugmakers race to find a place in the next wave of obesity drugs
June 13, 2026  |  cnbc.comhttps://www.cnbc.com/2026/06/13/glp-1s-lilly-novo-pfizer-look-to-new-weight-loss-drugs.html
Roche and Zealand Advance Combo Obesity Drug Trial, Signaling New Momentum for ZLDPF
June 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/roche-and-zealand-advance-combo-obesity-drug-trial-signaling-new-momentum-for-zldpf?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
June 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-23-2026-1036232504
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
June 8, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/zealand-pharma-shares-slide-after-boehringer-study-shows-obesity-shots-side-effects-a624e7b4
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
June 8, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/zealand-pharma-loses-a-fifth-of-its-value-as-many-users-gave-up-taking-weight-loss-drug-during-trial-80293179
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
June 8, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/zealand-pharma-shares-drop-20-obesity-drug-side-effects-raise-concerns-2026-06-08/
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
June 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-to-participate-in-the-goldman-sachs-global-healthcare-conference-1036218169
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
June 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-22-2026-1036213643

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$39.27 +0.22 (+0.56%)
As of 10:43 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$36.16 +0.05 (+0.14%)
As of 10:46 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Oxford BioMedica stock logo

Oxford BioMedica OTCMKTS:OXBDF

$7.34 0.00 (0.00%)
As of 08/4/2026 12:02 PM Eastern

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Zealand Pharma A/S stock logo

Zealand Pharma A/S OTCMKTS:ZLDPF

$47.50 0.00 (0.00%)
As of 08/4/2026

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas